Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · see citing works

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061 · see citing works

International uniform response criteria for multiple myeloma

Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · see citing works

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257 · see citing works

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037 · see citing works

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036 · see citing works

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,027 · see citing works

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Kaplan, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 991 · see citing works

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B. M. P., Bald, J., Plesner, T., Syed, K. W., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 961 · see citing works

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

Munshi, N. C., Avet‐Loiseau, H., Rawstron, A. C., Owen, R. G., Child, J. A., Thakurta, A., Sherrington, P. D., Samur, M., Georgieva, A., Anderson, K. C., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3160 · Cited by 540 · see citing works

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · see citing works

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Paiva, B., Vídriales, M., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M.-Á., Sureda, A. M., Montejano, L., Gutierrez, N. C., de Coca, A. G., et al. (2008) · Blood · doi:10.1182/blood-2008-05-159624 · Cited by 475 · see citing works

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Mateos, M., Cavo, M., Bladé, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 447 · see citing works

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550020 · Cited by 425 · see citing works

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Perrot, A., Lauwers‐Cancès, V., Corre, J., Robillard, N., Hulin, C., Chrétien, M., Dejoie, T., Mahéo, S., Stoppa, A., Pegourié, B., et al. (2018) · Blood · doi:10.1182/blood-2018-06-858613 · Cited by 420 · see citing works

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Rawstron, A. C., Child, J. A., Tute, R. M. D., Davies, F. E., Gregory, W. M., Bell, S., Szubert, A. J., Navarro-Coy, N. C., Drayson, M. T., Feyler, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2119 · Cited by 414 · see citing works

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Lahuerta, J. J., Paiva, B., Vídriales, M., Cordón, L., Cedena, M., Puig, N., Martínez‐López, J., Rosiñol, L., Gutierrez, N. C., Martín-Ramos, M.-L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2517 · Cited by 317 · see citing works

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297 · see citing works

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Lammerts van Bueren, J., Jakobs, D., Kaldenhoven, N., Roza, M., Hiddingh, S., Meesters, J., Voorhorst, M., Gresnigt, E., Wiegman, L., Ortiz Buijsse, A., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3474.3474 · Cited by 222 · see citing works

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis

Landgren, O., Devlin, S. M., Boulad, M., & Mailankody, S. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.222 · Cited by 196 · see citing works

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Adams, H., Stevenaert, F., Krejcik, J., der Borght, K. V., Smets, T., Bald, J., Abraham, Y., Ceulemans, H., Chiu, C. W., Vanhoof, G., et al. (2018) · Cytometry Part A · doi:10.1002/cyto.a.23693 · Cited by 163 · see citing works

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

Avet‐Loiseau, H., Ludwig, H., Landgren, O., Paiva, B., Morris, C., Yang, H., Zhou, K., Ro, S. K., & Mateos, M. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.622 · Cited by 130 · see citing works

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

Casneuf, T., Adams, H., van de Donk, N. W. C. J., Abraham, Y., Bald, J., Vanhoof, G., der Borght, K. V., Smets, T., Foulk, B., Nielsen, K. C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0855-4 · Cited by 123 · see citing works

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches

Kostopoulos, I. V., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Tsitsilonis, O., & Terpos, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00860 · Cited by 57 · see citing works

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Bahlis, N. J., Facon, T. T. F., Usmani, S. Z., Kumar, S. K., Plesner, T., Orlowski, R. Z., Touzeau, C., Basu, S., Nahi, H., Hulin, C., et al. (2019) · Blood · doi:10.1182/blood-2019-123426 · Cited by 37 · see citing works

Teclistamab in Relapsed or Refractory Multiple Myeloma

Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · see citing works

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Costa, L. J., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T. M., Godby, K. N., Silbermann, R. W., Dhakal, B., Bal, S., Giri, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00236-3 · Cited by 176 · see citing works

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Leypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01696 · Cited by 150 · see citing works

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Landgren, O., Prior, T. J., Masterson, T., Heuck, C., Bueno, O. F., Dash, A. B., Einsele, H., Goldschmidt, H., Knop, S., Li, C., et al. (2024) · Blood · doi:10.1182/blood.2024024371 · Cited by 131 · see citing works

Multiple myeloma with high-risk cytogenetics and its treatment approach

Hanamura, I. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03353-5 · Cited by 122 · see citing works

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Leleu, X. P., Hulin, C., Lambert, J., Bobin, A., Perrot, A., Karlin, L., Roussel, M., Montes, L., Chérel, B., Chalopin, T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03050-2 · Cited by 121 · see citing works

How I treat multiple myeloma in geriatric patients

Facon, T. T. F., Leleu, X. P., & Manier, S. (2023) · Blood · doi:10.1182/blood.2022017635 · Cited by 72 · see citing works

ENPP1 Immunobiology as a Therapeutic Target

de Córdoba, B. R., Martínez‐Monge, R., & Lecanda, F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1681 · Cited by 76 · see citing works

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Badros, A. Z., Foster, L. H., Anderson, L. D., Chaulagain, C. P., Pettijohn, E. M., Cowan, A. J., Costello, C. L., Larson, S. M., Sborov, D. W., Shain, K. H., et al. (2024) · Blood · doi:10.1182/blood.2024025746 · Cited by 67 · see citing works

MRD in multiple myeloma: does CR really matter?

Paiva, B., Miguel, J. F. S., & Avet‐Loiseau, H. (2022) · Blood · doi:10.1182/blood.2022016170 · Cited by 65 · see citing works

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

Facon, T. T. F., Moreau, P., Weisel, K. C., Goldschmidt, H., Usmani, S. Z., Chari, A., Plesner, T., Orlowski, R. Z., Bahlis, N. J., Basu, S., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02505-2 · Cited by 63 · see citing works

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Paiva, B., Manrique, I., Dimopoulos, M. A., Gay, F., Min, C., Zweegman, S., Špıčka, I., Teipel, R., Mateos, M., Giuliani, N., et al. (2022) · Blood · doi:10.1182/blood.2022016782 · Cited by 62 · see citing works

Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review)

Ge, Q., Zhang, Z., Li, S.-N., Ma, J., & Zhao, Z. (2024) · Oncology Letters · doi:10.3892/ol.2024.14681 · Cited by 57 · see citing works

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

Medina, A., Sarasquete, M. E., Jiménez, C., Puig, N., & García‐Sánz, R. (2023) · Cancers · doi:10.3390/cancers15143687 · Cited by 60 · see citing works

Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

Maura, F., Boyle, E. M., Coffey, D. G., Maclachlan, K. H., Gagler, D. C., Diamond, B. T., Ghamlouch, H., Blaney, P., Ziccheddu, B., Cirrincione, A. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00657-1 · Cited by 55 · see citing works

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Carretero-Iglesia, L., Hall, O. J., Berret, J., Pais, D., Estoppey, C., Chimen, M., Monney, T., Loyau, J., Dreyfus, C., Macoin, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00821-1 · Cited by 56 · see citing works

How I treat high-risk multiple myeloma

Zamagni, E., Barbato, S., & Cavo, M. (2021) · Blood · doi:10.1182/blood.2020008733 · Cited by 45 · see citing works

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Derman, B. A., Major, A., Cooperrider, J. H., Jiang, K., Ramsland, A., Karrison, T. G., Kubicki, T., & Jakubowiak, A. J. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01156-x · Cited by 44 · see citing works

Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

Shi, Q., Paiva, B., Pederson, L., Dimier, N., Talpes, E., Prior, T. J., Órfão, A., Moreau, P., Sonneveld, P., Kumar, S. K., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02020 · Cited by 44 · see citing works

Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible

Engelhardt, M. M., Kortüm, K. M., Goldschmidt, H., & Merz, M. (2024) · Haematologica · doi:10.3324/haematol.2023.283058 · Cited by 41 · see citing works

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Guerrero, C., Puig, N., Cedena, M., Calasanz, M. J., Gutierrez, N. C., Fernández, M., Oriol, A., Ríos, R., Hernandez, M.-T., Martínez-Martinez, R., et al. (2023) · Blood · doi:10.1182/blood.2023022083 · Cited by 40 · see citing works

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

D’Agostino, M., Bertuglia, G., Rota‐Scalabrini, D., Belotti, A., Morè, S., Corradini, P., Oliva, S., Ledda, A., Grasso, M., Pavone, V., et al. (2023) · Blood · doi:10.1182/blood.2023022080 · Cited by 39 · see citing works

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

Guerrero, C., Puig, N., Cedena, M., Goicoechea, I., Pérez, C., Garcés, J., Botta, C., Calasanz, M. J., Gutierrez, N. C., Martín-Ramos, M.-L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3430 · Cited by 39 · see citing works

Potential future direction of measurable residual disease evaluation in multiple myeloma

Mohty, M., Avet‐Loiseau, H., Malard, F., & Harousseau, J. (2023) · Blood · doi:10.1182/blood.2023020284 · Cited by 33 · see citing works

Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma

Paiva, B., Shi, Q., Puig, N., Cedena, M., Órfão, A., Durie, B. G. M., Munshi, N. C., & Miguel, J. F. S. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01017-x · Cited by 31 · see citing works

Targeted immunotherapy: harnessing the immune system to battle multiple myeloma

Xu, L., Wen, C., Xia, J., Zhang, H., Liang, Y., & Xu, X. G. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01818-6 · Cited by 30 · see citing works

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Corre, J., Vincent, L., Moreau, P., Hébraud, B., Hulin, C., Béné, M. C., Broijl, A., Caillot, D., Delforge, M., Dejoie, T., et al. (2025) · Blood · doi:10.1182/blood.2024027620 · Cited by 29 · see citing works

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

Mateos, M., Miguel, J. F. S., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Pour, L., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00018-x · Cited by 29 · see citing works

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

Oliva, S., Genuardi, E., París, L., D’Agostino, M., Rogers, J., Rota‐Scalabrini, D., Jacob, A. P., Patriarca, F. F., Luppi, M., Bertazzoni, P., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102016 · Cited by 28 · see citing works

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Puig, N., Agulló, C., Sanfeliciano, T. C., Cedena, M., Martínez‐López, J., Oriol, A., Blanchard, M. J., Ríos, R., Íñigo, M.-B., Sureda, A. M., et al. (2024) · Blood · doi:10.1182/blood.2024024995 · Cited by 27 · see citing works

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

Ocio, E. M., Perrot, A., Bories, P., Miguel, J. F. S., Blau, I. W., Karlin, L., Martínez‐López, J., Wang, S., Bringhen, S., Marcatti, M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01936-7 · Cited by 27 · see citing works

Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy

Rocchi, S., Zannetti, B. A., Marconi, G., & Lanza, F. (2024) · Cells · doi:10.3390/cells13100853 · Cited by 29 · see citing works

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

Meseha, M., Hoffman, J. E., Kazandjian, D. G., Landgren, O., & Diamond, B. T. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01537-2 · Cited by 25 · see citing works

Minimal residual disease in multiple myeloma: why, when, where

Yee, A. J., & Raje, N. S. (2021) · Hematology · doi:10.1182/hematology.2021000230 · Cited by 24 · see citing works

Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting

Bonello, F., Cani, L., & D’Agostino, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830922 · Cited by 21 · see citing works

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

Fan, H., Wang, B., Shi, L., Pan, N., Yan, W., Xu, J., Gong, L., Li, L., Liu, Y., Du, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2767 · Cited by 22 · see citing works

The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?

Giles, H. V., Wechalekar, A. D., & Pratt, G. (2022) · British Journal of Haematology · doi:10.1111/bjh.18226 · Cited by 21 · see citing works

Measurable Residual Disease and Decision-Making in Multiple Myeloma

Derman, B. A., & Fonseca, R. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.009 · Cited by 21 · see citing works

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

Fan, H., #x0026, & #x0026 (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0612 · Cited by 20 · see citing works

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma

Lasa, M., Notarfranchi, L., Agulló, C., González, C., Castro, S., Pérez, J. J., Burgos, L., Guerrero, C., Calasanz, M. J., Flores-Montero, J. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00635 · Cited by 18 · see citing works

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

Perrot, A., Delimpasi, S., Spanoudakis, E., Frølund, U. C., Belotti, A., Oriol, A., Moreau, P., McFadden, I., Xia, Q., Arora, M., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2322030 · Cited by 17 · see citing works

Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

Botta, C., Gigliotta, E., Paiva, B., Anselmo, R., Santoro, M., Rodríguez‐Otero, P., Carlisi, M., Conticello, C., Romano, A., Solimando, A. G., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3041 · Cited by 15 · see citing works

Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma

Wang, J., Li, J., Zhang, R., Li, J., Chen, L., & Jin, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-00891-8 · Cited by 15 · see citing works

Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis

Ficek, J., Kalaitzaki, E., Yuan, S. S., Tosolini, A., Du, L., Kremer, B. E., Davy, K., Zhou, H., & Chen, T. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.005 · Cited by 15 · see citing works

New Strategies for the Treatment of Older Myeloma Patients

Larocca, A., Cani, L., Bertuglia, G., Bruno, B., & Bringhen, S. (2023) · Cancers · doi:10.3390/cancers15102693 · Cited by 13 · see citing works

Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database

Wu, J., Wu, H.-B., Chen, L., Liang, H., Huang, G., Yang, S., Chen, B., Noguchi, Y., & Shen, Y. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2296966 · Cited by 13 · see citing works

M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma

Guan, L., Su, W., Zhong, J., & Qiu, L. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117623 · Cited by 12 · see citing works

Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myeloma

Cho, H., Shin, S., Chung, H., Jang, J. E., Kim, Y. R., Cheong, J., Min, Y. H., Lee, S., Choi, J. R., & Kim, J. S. (2022) · British Journal of Haematology · doi:10.1111/bjh.18211 · Cited by 12 · see citing works

High or low? Assessing disease risk in multiple myeloma

Schmidt, T. M. (2022) · Hematology · doi:10.1182/hematology.2022000347 · Cited by 12 · see citing works

Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs

Cordone, I., Amodeo, R., Bellesi, S., Bottan, F., Buccisano, F., Propris, M. S. D., Masi, S., Panichi, V., Scerpa, M. C., Annibali, O., et al. (2023) · Cancers · doi:10.3390/cancers15072060 · Cited by 11 · see citing works

Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T‐cell redirecting immunotherapy

Zabaleta, A., Puig, N., Cedena, M., Oliver‐Caldés, A., Pérez, J. J., Moreno, C., Tamariz‐Amador, L., Rodríguez‐Otero, P., Prósper, F., González‐Calle, V., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27526 · Cited by 11 · see citing works

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Liu, J., Yan, W., Fan, H., Xu, J., Li, L., Du, C., Mao, X., Yan, Y., Xu, Y., Sui, W., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0185 · Cited by 10 · see citing works

Real‐World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry

Muroňová, L., Souček, O., Žihala, D., Ševčíková, T., Popková, T., Plonková, H., Venglár, O., Pour, L., Štork, M., Říhová, L., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14316 · Cited by 11 · see citing works

Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma

An, N., Li, J., Luo, P., Wang, D., Zhang, P., Shu, C., Cai, S., Yu, Q., Wen, X., Wang, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06543-x · Cited by 10 · see citing works

Knowing the unknowns in high risk multiple myeloma

Derman, B. A., Kosuri, S., & Jakubowiak, A. J. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100887 · Cited by 10 · see citing works

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

Morè, S., Corvatta, L., Manieri, V. M., Morsia, E., & Offidani, M. (2024) · Cancers · doi:10.3390/cancers16122263 · Cited by 9 · see citing works

Management recommendations for kidney transplantation in patients with plasma cell dyscrasia

Murakami, N., Blosser, C. D., Webber, A. B., Gupta, G., Singh, N., Boppana, S., Master, S. R., Parasuraman, R. K., Campagnaro, E. L., Java, A., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.07.011 · Cited by 9 · see citing works

Clinical applications of mass spectrometry in multiple myeloma

Derman, B. A., & Yee, A. J. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015685 · Cited by 9 · see citing works

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

Tang, W., Zhang, L., Zheng, Y., Pan, L., & Niu, T. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1286029 · Cited by 9 · see citing works

MRD end point in myeloma: ready for prime time?

Quach, H. (2022) · Blood · doi:10.1182/blood.2021013363 · Cited by 9 · see citing works

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial

Puig, N., Agulló, C., Contreras, T., Pérez, J.-J., Aires‐Mejía, I., Calasanz, M. J., García‐Sánz, R., Castro, S., Martínez‐López, J., Rodríguez‐Otero, P., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285742 · Cited by 8 · see citing works

Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy

Cooperrider, J. H., & Derman, B. A. (2025) · Drugs · doi:10.1007/s40265-025-02232-7 · Cited by 8 · see citing works

Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting

Solimando, A. G., Krebs, M., Desantis, V., Marziliano, D., Caradonna, I. C., Morizio, A., Argentiero, A., Shahini, E., & Bittrich, M. (2023) · Biomedicines · doi:10.3390/biomedicines11072087 · Cited by 8 · see citing works

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

Ramasamy, K., Avet‐Loiseau, H., Blimark, C. H., Delforge, M., Gay, F., Manier, S., Martínez‐López, J., Mateos, M., Mohty, M., van de Donk, N. W. C. J., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000942 · Cited by 7 · see citing works

MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma

Chen, L. Y., Thibaud, S., Bodnar, S., Chari, A., Richter, J. R., Cho, H. J., Sanchez, L. J., Rodriguez, C., Rossi, A., Richard, S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014097 · Cited by 7 · see citing works

Toward a cure for multiple myeloma within a decade

Mohty, M., Malard, F., Facon, T. T. F., & Harousseau, J. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01461-7 · Cited by 7 · see citing works

Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes–A feasibility study

Marx, A., Osváth, M., Szikora, B., Pipek, O., Csabai, I., Nagy, Á., Bödör, C., Matula, Z., Nagy, G., Bors, A., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285696 · Cited by 7 · see citing works

Personalized Treatment of Multiple Myeloma in Frail Patients

Lipof, J. J., Abdallah, N. H., & Lipe, B. C. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01545-2 · Cited by 7 · see citing works

Minimal residual disease in multiple myeloma

Moukalled, N. M., Malard, F., Bazarbachi, A. A., & Mohty, M. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104261 · Cited by 7 · see citing works

Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis

Osama, M., Khan, M. H., Khan, S., Hussain, A., Tahir, A., Ullah, M., Afridi, A., Ullah, U., & Rehman, W. U. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251314289 · Cited by 7 · see citing works

Current Main Topics in Multiple Myeloma

Morè, S., Corvatta, L., Manieri, V. M., Olivieri, A., & Offidani, M. (2023) · Cancers · doi:10.3390/cancers15082203 · Cited by 8 · see citing works

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis

Xu, W., Liang, X., Liu, S., Yi, X., Tian, M., Yue, T., Zhang, Y., Yan, Y., Lan, M., Long, M., et al. (2024) · Clinical Medicine · doi:10.1016/j.clinme.2024.100252 · Cited by 6 · see citing works

REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA

Martino, E. A., Mele, G., Morabito, F., Gentile, M., & Vigna, E. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2025.006 · Cited by 6 · see citing works

MRD-guided treatment cessation in multiple myeloma

Derman, B. A. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00240-5 · Cited by 6 · see citing works

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

Lakhwani, S., Rosiñol, L., Puig, N., Pico-Picos, M.-A., Medina-González, L., Martínez‐López, J., Paiva, B., Cedena, M., Oriol, A., Ríos, R., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.284154 · Cited by 6 · see citing works

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020

Oekelen, O. V., Birrer, N., Wesson, W., Galate, V. L., Cliff, E. R. S., Goodman, A. M., Abdallah, A.-O. A., Chakraborty, R., Prasad, V. K., & Mohyuddin, G. R. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00750-1 · Cited by 6 · see citing works

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

Partanen, A., Waage, A., Pečeliūnas, V., Schjesvold, F. H., Anttila, P. M., Säily, M., Uttervall, K., Putkonen, M., Carlson, K. E., Haukås, E., et al. (2024) · Cancers · doi:10.3390/cancers16051024 · Cited by 5 · see citing works

Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies

Shim, K. G., & Fonseca, R. (2024) · Cancers · doi:10.3390/cancers16193288 · Cited by 5 · see citing works

Next-generation immunotherapy in relapsed/refractory multiple myeloma: Strategies to achieve sustained MRD negativity

Zhu, L., Nawaz, M. A., Zuo, Y., & Zeng, P. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104913 · Cited by 5 · see citing works

Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line

Hartley-Brown, M. A., & Zinkeng, A. (2023) · Hematology · doi:10.1182/hematology.2023000444 · Cited by 5 · see citing works

Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance

Firestone, R., Simhal, A. K., McAvoy, D. P., Jurgens, E. M., Garcés, J., Nemirovsky, D., Derkach, A., Maclachlan, K. H., Hultcrantz, M. L., Mailankody, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0572 · Cited by 4 · see citing works

Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma

Gan, X., Li, L., Zhang, L., Zheng, Y., Niu, T., & Yu, Z. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01199-z · Cited by 4 · see citing works

Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma

Nahi, H., Afram, G., Uttervall, K., Lockmer, S., Tӓtting, L., Gahrton, G., Kashif, M., Alici, E., Strömberg, O., Klimkowska, M., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6640 · Cited by 3 · see citing works

Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma

Abdallah, N. H., & Kumar, S. K. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7039 · Cited by 4 · see citing works

Treatment of elderly and frail myeloma patients

Shih, S. C.-M., Visram, A., & Mian, H. S. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104266 · Cited by 4 · see citing works

Moving Toward a Cure in Multiple Myeloma: Eradication of Measurable Residual Disease

Derman, B. A., & Jakubowiak, A. J. (2022) · Advances in Oncology · doi:10.1016/j.yao.2022.02.012 · Cited by 4 · see citing works

Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?

Caetano, J., Barahona, F., Lúcio, P., & Joao, C. M. (2022) · Hemato · doi:10.3390/hemato3030027 · Cited by 4 · see citing works

Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone

Yoroidaka, T., YAMASHITA, T., Murata, R., Yoshihara, K., Yoshihara, S., Ueda, M., Nakao, S., Matsue, K., & Takamatsu, H. (2022) · Anticancer Research · doi:10.21873/anticanres.16145 · Cited by 4 · see citing works

MRD negativity: considerations for older adults with multiple myeloma

Mian, H. S., Wildes, T. M., Venner, C. P., & Fonseca, R. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00939-y · Cited by 4 · see citing works

Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup

Ding, J., & Gong, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398879 · Cited by 3 · see citing works

Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada

Mian, H. S., Visram, A., Shih, S. C.-M., Trudel, S., Hay, A. E., LeBlanc, R., Sébag, M., Kaedbey, R., Stakiw, J., Sandhu, I., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.010 · Cited by 3 · see citing works

Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Sudha, P., Johnson, T. S., Hamidi, H., Yang, K., Liu, E., Smith, B., Chopra, V. S., Nixon, M., Zafar, F., Farag, S. S., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0019 · Cited by 3 · see citing works

Circulating extracellular vesicle isomiR signatures predict therapy response in patients with multiple myeloma

Gómez‐Martín, C., Drees, E. E. E., van Eijndhoven, M. A. J., Groenewegen, N. J., Wang, S., Verkuijlen, S. A. W. M., van Weering, J. R. T., Aparicio‐Puerta, E., Bosch, L., Frerichs, K. A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102358 · Cited by 3 · see citing works

Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application

Mina, R., Antonioli, E., Barilà, G., Bolli, N., Botta, C., Furlan, A., Liberatore, C., Martello, M., Móre, S. M. C., Oliva, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.016 · Cited by 3 · see citing works

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)

Bahlis, N. J., Costa, L. J., Facon, T. T. F., Harousseau, J., Manier, S., Perrot, A., Touzeau, C., & Mohty, M. (2023) · Clinical Hematology International · doi:10.1007/s44228-023-00036-8 · Cited by 3 · see citing works

Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma

Cui, J., Yu, T., Lv, R., Liu, J., Fan, H., Yan, W., Xu, J., Du, C., Deng, S., Sui, W., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231221340 · Cited by 3 · see citing works

Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies

Costa, L. J., Gay, F., Landgren, O., Mateos, M., Moreau, P., Touzeau, C., Ertel, F., McFadden, I., Najdi, R., & Weisel, K. C. (2025) · Annals of Hematology · doi:10.1007/s00277-024-06143-7 · Cited by 3 · see citing works

Challenges in Multiple Myeloma Therapy in Older and Frail Patients

Aureli, A., Marziani, B., Sconocchia, T., Pasqualone, G., Franceschini, L., Spagnoli, G. C., Venditti, A., & Sconocchia, G. (2025) · Cancers · doi:10.3390/cancers17060944 · Cited by 3 · see citing works

Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?

Bertuglia, G., Cani, L., Larocca, A., Gay, F., & D’Agostino, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415879 · Cited by 3 · see citing works

Sustained minimal residual disease in myeloma

Bianchi, G. (2022) · Blood · doi:10.1182/blood.2021013199 · Cited by 3 · see citing works

Multiples Myelom: Korrelation zwischen minimaler Resterkrankung und progressionsfreiem Überleben

Hajiyianni, M., & Goldschmidt, H. (2023) · Kompass Onkologie · doi:10.1159/000529718

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Miguel, J. F. S., Avet‐Loiseau, H., Paiva, B., Kumar, S. K., Dimopoulos, M. A., Facon, T. T. F., Mateos, M., Touzeau, C., Jakubowiak, A. J., Usmani, S. Z., et al. (2020) · Blood · doi:10.1182/blood-2020-134928 · Cited by 3 · see citing works

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Cavo, M., Miguel, J. F. S., Usmani, S. Z., Weisel, K. C., Dimopoulos, M. A., Avet‐Loiseau, H., Paiva, B., Bahlis, N. J., Plesner, T., Hungria, V., et al. (2021) · Blood · doi:10.1182/blood.2021011101 · Cited by 106 · see citing works

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Avet‐Loiseau, H., Miguel, J. F. S., Casneuf, T., Iida, S., Lonial, S., Usmani, S. Z., Spencer, A. G., Moreau, P., Plesner, T., Weisel, K. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01814 · Cited by 94 · see citing works

C002 | SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NDMM: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN THE PHASE 3 PERSEUS TRIAL

Antonioli, E., Moreau, P., Sonneveld, P., Einsele, H., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Leleu, X. P., Mangiacavalli, S., et al. (2025) · DOAJ (DOAJ: Directory of Open Access Journals)